What is CEL-SCI Corporation (CVM)?

CEL-SCI Corporation (CVM) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CVM?

The current price of CVM is $1.60. Prices are updated in real time on Stocks360.

What is CVM's price-to-earnings (PE) ratio?

CVM's trailing twelve-month PE ratio is -0.62, based on current price and earnings per share data available on Stocks360.

What is CVM's market capitalization?

CVM's market capitalization is $28,142,376.00, placing it in the small-cap tier.

CEL-SCI Corporation (CVM)

Stock analysis · AMEX · Healthcare · Biotechnology

$1.60

Market Cap

$28.14M

PE (TTM)

-0.62

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.59

Day Range

$1.55 – $1.62

52-wk Range

$0.89 – $8.43

Avg Volume

N/A

Volume

98.35K

CEL-SCI Corporation (CVM) is a publicly traded company in the Healthcare sector. Latest price: $1.60. Market cap $28.14M. Trailing PE -0.62. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $7.59 2026-10-28 · $1.60 (-78.92%)

Earnings

Most Recent

Jan 13, 2025

EPS $-3.07 vs est. $-0.11

Missed by $2.96

Next Earnings

Dec 23, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About CEL-SCI Corporation

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.62×
P/S (TTM)	0.00×
P/B	1.77×
P/FCF (TTM)	-1.68×
EV / EBITDA	-1.60×
EV / Sales	0.00×
Earnings Yield	-117.11%
Free Cash Flow Yield	-59.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$29.51M
Net Income (TTM)	-$32.96M
Free Cash Flow (TTM)	-$16.31M
Net Debt	$1.37M
Working Capital	$2.42M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-202.14%
Return on Invested Capital	-117.44%